Real-world effectiveness of influenza vaccine over a decade during the 2011-2021 seasons-Implications of vaccine mismatch
- PMID: 39362009
- DOI: 10.1016/j.vaccine.2024.126381
Real-world effectiveness of influenza vaccine over a decade during the 2011-2021 seasons-Implications of vaccine mismatch
Abstract
Background: Influenza imposes a significant healthcare burden in Korea, leading the government to initiate a national immunization program. Previous studies on vaccine effectiveness (VE) were limited to single-season estimation in Korea.
Methods: This multicenter prospective cohort study enrolled patients with influenza-like illnesses at 10 medical centers in Korea from 2011 to 2021. The demographic and clinical data were collected from questionnaire surveys and electronic medical records. Using a test-negative design, we aimed to investigate the effectiveness of a seasonal influenza vaccine for antigenic matching of the vaccine and circulating viral strains over 10 seasons.
Results: Overall, 5322 adults aged ≥65 years were enrolled. Only three (33.3 %) of nine seasons showed >70 % antigenic match between vaccine and circulating strains. Influenza VE was significantly variable by season, ranging from -46.9 % (95 %confidence interval [CI]: -127.6-5.2) in the 2011/12 season to 47.7 % (95 %CI: 22.6-64.7) in the 2016/17 season. A significant difference was observed in the VE depending on whether the vaccine strains matched with epidemic strains: 28.8 % (95 %CI: 8.8-44.8) in matched seasons versus -12.0 % (95 %CI: -30.0-3.7) in mismatched seasons. Across the study period, influenza-related hospitalizations were reduced by 13.6 % (95 %CI: 0.7-24.8) with vaccination. In a subgroup analysis, the VE against influenza-related hospitalization was 48.4 % (95 %CI 29.6-62.2) in A/H3N2 dominant seasons and 53.8 % (95 %CI: -73.4-87.7) in A/H1N1 dominant seasons, respectively.
Conclusion: Influenza vaccine mismatch was frequent over the study period, leading to negligibly low VE in mismatched seasons. Influenza vaccination reduces the risk of influenza-related hospitalizations.
Keywords: Hospitalization; Influenza; Influenza vaccine; Vaccine; Vaccine effectiveness.
Copyright © 2024. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hee Jin Cheong reports financial support was provided by Korea University College of Medicine. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
The Impact of Prior Season Vaccination on Subsequent Influenza Vaccine Effectiveness to Prevent Influenza-related Hospitalizations Over 4 Influenza Seasons in Canada.Clin Infect Dis. 2019 Aug 30;69(6):970-979. doi: 10.1093/cid/ciy1009. Clin Infect Dis. 2019. PMID: 30508064
-
Influenza vaccine effectiveness against hospitalization with laboratory-confirmed influenza in Greece: A pooled analysis across six seasons, 2013-2014 to 2018-2019.Vaccine. 2020 Mar 10;38(12):2715-2724. doi: 10.1016/j.vaccine.2020.01.083. Epub 2020 Feb 6. Vaccine. 2020. PMID: 32033848
-
Influenza vaccine effectiveness in preventing hospitalizations with laboratory-confirmed influenza in Greece during the 2014-2015 season: A test-negative study.J Med Virol. 2016 Nov;88(11):1896-904. doi: 10.1002/jmv.24551. Epub 2016 Apr 26. J Med Virol. 2016. PMID: 27088266
-
Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies.J Infect Dis. 2018 Feb 14;217(5):731-741. doi: 10.1093/infdis/jix632. J Infect Dis. 2018. PMID: 29220496
-
Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta-analysis.Influenza Other Respir Viruses. 2021 Mar;15(2):293-314. doi: 10.1111/irv.12814. Epub 2020 Sep 30. Influenza Other Respir Viruses. 2021. PMID: 32997395 Free PMC article.
Cited by
-
H3 hemagglutinin proteins optimized for 2018 to 2022 elicit neutralizing antibodies across panels of modern influenza A(H3N2) viruses.J Immunol. 2025 Jul 1;214(7):1698-1713. doi: 10.1093/jimmun/vkaf092. J Immunol. 2025. PMID: 40400055
-
The Ongoing Epidemics of Seasonal Influenza A(H3N2) in Hangzhou, China, and Its Viral Genetic Diversity.Viruses. 2025 Apr 4;17(4):526. doi: 10.3390/v17040526. Viruses. 2025. PMID: 40284969 Free PMC article.
-
Analysis of Epidemiological and Evolutionary Characteristics of Seasonal Influenza Viruses in Shenzhen City from 2018 to 2024.Viruses. 2025 May 30;17(6):798. doi: 10.3390/v17060798. Viruses. 2025. PMID: 40573388 Free PMC article.
-
Optimizing Influenza Vaccine Protection in India.Indian Pediatr. 2025 Jul 22. doi: 10.1007/s13312-025-00119-0. Online ahead of print. Indian Pediatr. 2025. PMID: 40694287 Review.
-
Genetic Evolution of the Hemagglutinin Genes of Seasonal Influenza A Viruses in Türkiye Between 2017 and 2023.Influenza Other Respir Viruses. 2025 Jul;19(7):e70134. doi: 10.1111/irv.70134. Influenza Other Respir Viruses. 2025. PMID: 40576308 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical